Bosentan in pulmonary hypertension associated with hypoxaemic lung diseases
| Autor: | D. Vielba Ramos, I. Ramos Cancelo, E. Abad Lecha, V. Roig Figueroa, A. Herrero Pérez |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
COPD
medicine.medical_specialty Bronchiectasis Lung business.industry Endothelin receptor antagonist General Medicine medicine.disease Pulmonary hypertension Bosentan respiratory tract diseases Pulmonary function testing Idiopathic pulmonary fibrosis medicine.anatomical_structure Internal medicine Cardiology Medicine business medicine.drug |
| Zdroj: | Current Medical Research and Opinion. 23:S49-S53 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1185/030079907x199538 |
| Popis: | Background: Pulmonary hypertension (PH) is associated with limitation of exercise capacity, poor clinical course and reduced survival in chronic, hypoxaemic lung diseases. Bosentan is an oral dual endothelin receptor antagonist with established efficacy in pulmonary arterial hypertension, either idiopathic or associated with other diseases. Treatment experience with the efficacy and safety of bosentan in PH associated with chronic hypoxeamic lung diseases is limited.Methods: This case-series study reports six consecutive patients with chronic hypoxaemia on the basis of COPD, idiopathic pulmonary fibrosis, silicosis, pneumonectomy, or bronchiectasis. All patients were on long-term oxygen therapy.Results: After 12 weeks’ bosentan treatment, mean 6-minute walk distance increased by 44 meters (from 317 ± 40 m to 361 ± 43 m) and two patients had improved their functional class. Mean systolic pulmonary arterial pressure (PAP) decreased from 83 ± 5.3 to 75 ± 6.1 mmHg, mean partial pressure of arterial ox... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|